Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

Core Insights - The article highlights the successful development and approval of the innovative drug "Taretnib" by Baoyuan Pharmaceutical, marking a significant milestone for Chinese pharmaceutical innovation on the global stage [2][6] Group 1: Drug Development and Approval - Taretnib is the first Class 1 innovative drug to emerge from the Hangzhou Medical Port, recently receiving approval from Japan's Ministry of Health, Labor and Welfare, following its approval in the United States [2] - The drug targets a specific genetic mutation in non-small cell lung cancer, which affects only 1% to 3.4% of patients, yet represents a breakthrough opportunity for Chinese innovation in pharmaceuticals [3] Group 2: Company Strategy and Collaboration - Baoyuan Pharmaceutical adopts a "global rights, global development" strategy, collaborating with partners in China, South Korea, and Japan to enhance clinical development and commercialization efforts [4] - The company has successfully navigated the drug approval process, benefiting from China's accelerated drug approval system, particularly under the "14th Five-Year Plan" which emphasizes support for the biopharmaceutical industry [6] Group 3: Industry Growth and Impact - The biopharmaceutical industry in Hangzhou has seen significant growth, with the number of pharmaceutical production companies increasing from 94 to 133 and wholesale companies from 167 to 318 over the past five years, reflecting an average growth rate of 83% [7] - The successful acquisition of Baoyuan Pharmaceutical by a U.S. biopharmaceutical company underscores the global recognition of Chinese innovative drugs, completing a cycle of internationalization from development to market acceptance [7]

Summary of China Clinical CRO Expert Call Industry Overview - **Industry**: Clinical Contract Research Organizations (CROs) in China - **Key Company**: Tigermed Core Insights 1. **2026 Outlook**: The expert predicts a better outlook for 2026 for the Chinese CRO industry, with expectations of less fierce price competition and increased overseas pharmaceutical and biotech trials due to cost and speed advantages [1][2][3] 2. **Price Recovery**: Smaller CROs are struggling, leading to industry prices being 30-40% lower than in 2022. Leaders like Tigermed are expected to recover first, with a gradual price increase anticipated in 2026 [2][3] 3. **Client Demand**: Demand from multinational corporations (MNCs) and large domestic pharmaceutical companies remains resilient, with increasing demand from domestic biotech firms. A pickup in client demand was noted starting in July 2025 [3][4] 4. **FDA Concerns**: Despite concerns raised by the US FDA regarding the quality of Phase 3 trial data from China, the expert believes that Chinese data meets global standards, adhering to ICH guidelines [4][5] 5. **Global Attraction**: China is becoming a preferred location for overseas biotech companies to conduct clinical trials, particularly Phase I trials, due to its cost and operational speed advantages compared to the US, Europe, and Australia [5][7] 6. **AI Integration**: The integration of AI in clinical trials is expected to enhance efficiency by improving trial design, accelerating patient matching, and assisting with medical writing and translation [8] Additional Insights 1. **Global Expansion of Chinese CROs**: The expert suggests that Chinese CROs can expand globally through partnerships, acquisitions, and attracting overseas clients for early-phase trials in China [9] 2. **Cost Comparisons**: The expert highlighted significant cost advantages for conducting trials in China, with Phase I trials costing substantially less than in the US and Europe, and even higher disparities for certain conditions like ophthalmic diseases [7] 3. **Valuation of Tigermed**: The target price for Tigermed is set at Rmb67 based on an NPV-based SOTP valuation, with contributions from clinical trial solutions, laboratory services, and investment income [10][12] 4. **Risks**: Potential risks affecting Tigermed's share price include weaker-than-expected client orders, intense market competition, and margin pressures due to overseas expansion and AI investments [11][13] This summary encapsulates the key points discussed during the expert call, providing insights into the current state and future outlook of the Chinese CRO industry, particularly focusing on Tigermed.

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 杭州泰格醫藥科技股份有限公司 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞 增 玉 先 生；獨 立 非 執 行 董 事 為 廖 啟 宇 先 生、袁 華 剛 先 生 ...

杭州泰格医药科技股份有限公司 第五届董事会第二十次会议决议公告 证券代码：300347 证券简称：泰格医药 公告编码（2025）043 号 根据《公司法》《公司章程》的规定，原《公司法》监事会规定的职权由审计委员会 行使。董事会确认公司第五届董事会审计委员会仍由廖启宇先生、袁华刚先生、刘毓文女 士组成，召集人仍由廖启宇先生担任。任期自本次董事会审议通过之日起至第五届董事会 届满之日止。 表决结果：同意7票，反对0票，弃权0票。 特此公告。 杭州泰格医药科技股份有限公司董事会 二〇二五年十二月十一日 1 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第二十次会议于2025 年12月9日在杭州市滨江区聚工路19号盛大科技园A座20层会议室举行，本次会议以现场与 通讯表决相结合的方式召开。全体董事一致同意豁免本次董事会会议的提前通知期限，会 议通知已于2025年12月8日以电话、电子邮件方式向全体董事发出。会议应到董事7人，实 到董事7人。本次会议由公司董事长叶小平先生主持。本次会议的召开及程序 ...

12月9日早盘，A股、港股创新药概念均表现活跃。热门ETF中，创新药ETF（159992）截至9:57涨约 1%，成交额超1.5亿元。 成分股来看，迪哲医药、恒瑞医药、泰格医药等涨幅居前；通化金马、人福医药、特宝生物等小幅领 跌。 消息面上，2025年国家医保药品目录及首版商保创新药目录在广州发布。2025年国家医保药品目录成功 新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首 版商保创新药目录。 每日经济新闻 中信建投认为，国家医保谈判成功率创新高，商保目录有望成为重要增量，政策鼓励创新药发展。与此 同时，中国创新药管线国际化竞争力持续提升，出海模式持续升级，新技术推动行业快速发展。看好相 关创新药及制药企业。 资料显示，创新药ETF（159992，场外联接A类：012781；C类：012782）紧密跟踪中证创新药产业指 数，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表 现。 ...

Group 1 - Hong Kong pharmaceutical stocks showed strong performance on December 9, with notable gains in several companies [2] - Gilead Sciences-B (01672.HK) experienced a significant increase of 14.93% [2] - Tigermed (03347.HK) rose by 2.91%, while WuXi AppTec (02268.HK) saw a modest increase of 0.97% [2]

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The report highlights the ongoing transformation in cancer treatment, moving from broad-spectrum therapies to precision medicine, with a focus on innovative technologies such as bispecific antibodies, antibody-drug conjugates (ADC), and CAR-T therapies [7][14] - It emphasizes the importance of companies with cutting-edge technology platforms and differentiated research strategies, particularly in the context of blood cancers becoming manageable chronic diseases [11][14] - The report suggests that the recent ESMO Asia and ASH conferences have positively influenced market sentiment, revealing clear directions for future cancer treatments [11][14] Summary by Sections Industry Overview - The pharmaceutical sector is experiencing significant internal differentiation, with some sub-sectors like pharmaceutical commerce and traditional Chinese medicine performing well, while others like medical devices and chemical pharmaceuticals are facing declines [7][11] - The total market capitalization of the industry is approximately 72,066.76 billion [2] Key Investment Directions - Focus on biotech companies with innovative technology platforms, particularly those developing new delivery systems and ADCs targeting specific cancer markers [11][14] - Look for companies implementing differentiated research strategies, especially in rare target areas and combination therapies [11][14] - Recognize the long-term investment value in blood cancers as they transition into manageable chronic conditions, expanding the market for existing and new therapies [11][14] Market Dynamics - The report notes that the pharmaceutical sector's performance has been mixed, with a year-to-date return of 15.86%, slightly lagging behind the broader market [11] - The report identifies key companies to watch, including 康方生物, 药明合联, and others, which are expected to perform well based on their innovative approaches and market positioning [8][11][14]

此外，评选覆盖多个维度并具备专业性。 为对企业财务、鉴证、治理结构、合规等方面进行系统评 估，评审团汇聚了来自全球顶尖机构与知名高校的专家学者。同时，依托妙盈科技、Wind ESG、商 道融绿三家数据合作伙伴的支持，我们整合了上万家中国企业的ESG信息，为评审提供了扎实的数据 基础。虎嗅ESG向各位合作伙伴表达诚挚谢意！ 历经两个月的公开征集与专业评审后， 2025"可持续品牌典范" 榜单已于近日正式揭晓。究竟哪些企 业真正将ESG融入战略，在可持续发展道路上走在了前列？让我们一同关注这份凝聚专业与诚意的年 度榜单。 在近200家入围企业中，我们最终评选出55家上榜企业，他们分享了本届全部11项荣誉（包括1项年 度大奖及10项专项奖）。从环境到社会再到治理，这些企业将社会责任融进自己的商业血脉中。 本次榜单的核心价值首先体现在其公正性上 ——整个评审过程完全独立，未受任何商业因素干扰。 其次，榜单的权威性源于严谨的规则设计。 我们特邀业内资深专家担任观察员，全程监督申报与评 审各个环节，确保流程公平、杜绝偏颇。 "2025可持续品牌典范"组委会成员包括： 评委团成员（排名不分先后，按首字母排序）：李岷（虎嗅网 ...